PURPOSE: The optimal schedule of irradiation in elderly patients suffering from glioblastoma multiforme (GBM) is unsettled. MATERIALS AND METHODS: This study reviewed the charts of 28 consecutive GBM patients aged 70 years or more with a Karnofsky Performance Status (KPS) greater than or equal to 70 who received a short course of radiotherapy (40 grays in 15 fractions over three weeks). RESULTS: The median age at surgery was 74.6 years (range, 70.1-85.7). No patient received prior or concomitant chemotherapy. The median progression-free survival and overall survival were 21.6 weeks (95% CI, 17.0-39.9) and 50.6 weeks (95% CI, 26.3-62.0), respectively. Even within a narrow range (<90 or >or=90), KPS remained a prognostic factor (p=0.03). Tolerance appeared acceptable in terms of KPS changes and corticosteroid use during radiation therapy. CONCLUSION: These results support the efficacy of short schedule radiotherapy for GBM in elderly patients with a good KPS.
PURPOSE: The optimal schedule of irradiation in elderly patients suffering from glioblastoma multiforme (GBM) is unsettled. MATERIALS AND METHODS: This study reviewed the charts of 28 consecutive GBM patients aged 70 years or more with a Karnofsky Performance Status (KPS) greater than or equal to 70 who received a short course of radiotherapy (40 grays in 15 fractions over three weeks). RESULTS: The median age at surgery was 74.6 years (range, 70.1-85.7). No patient received prior or concomitant chemotherapy. The median progression-free survival and overall survival were 21.6 weeks (95% CI, 17.0-39.9) and 50.6 weeks (95% CI, 26.3-62.0), respectively. Even within a narrow range (<90 or >or=90), KPS remained a prognostic factor (p=0.03). Tolerance appeared acceptable in terms of KPS changes and corticosteroid use during radiation therapy. CONCLUSION: These results support the efficacy of short schedule radiotherapy for GBM in elderly patients with a good KPS.
Authors: Christina Leitzen; Hans H Schild; Birgitta Bungart; Ulrich Herrlinger; Christiana Lütter; Thomas Müdder; Timo Wilhelm-Buchstab; Heinrich Schüller Journal: Strahlenther Onkol Date: 2010-11-29 Impact factor: 3.621
Authors: L Fariselli; V Pinzi; I Milanesi; A Silvani; M Marchetti; M Farinotti; A Salmaggi Journal: Strahlenther Onkol Date: 2013-04-28 Impact factor: 3.621
Authors: Marsha Reyngold; Andrew B Lassman; Timothy A Chan; Yoshiya Yamada; Philip H Gutin; Kathryn Beal Journal: J Neurooncol Date: 2012-09-16 Impact factor: 4.130
Authors: C Leitzen; T Wilhelm-Buchstab; L C Schmeel; S Garbe; S Greschus; T Müdder; S Oberste-Beulmann; B Simon; H H Schild; H Schüller Journal: Strahlenther Onkol Date: 2016-06-03 Impact factor: 3.621